Ekso Bionics Holdings, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual)

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2025 USD ($)	Jun. 30, 2024	Jun. 30, 2025 USD ($)	Jun. 30, 2024	Dec. 31, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Accounts Receivable, after Allowance for Credit Loss, Current	$ 4,533		$ 4,533		$ 7,238	$ 7,238	$ 5,645
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Number Of Customers			3		2
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer A [Member]
Concentration Risk, Percentage			15.00%		17.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer B [Member]
Concentration Risk, Percentage			14.00%		17.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer C [Member]
Concentration Risk, Percentage			13.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Number Of Customers	3	2	1	2
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer A [Member]
Concentration Risk, Percentage	18.00%	11.00%	14.00%	12.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer B [Member]
Concentration Risk, Percentage	13.00%	10.00%		10.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer C [Member]
Concentration Risk, Percentage	10.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details